Khan Abdul Waheed, Jandeleit-Dahm Karin A M
Department of Diabetes, Central Clinical School, Monash University, Melbourne, Victoria, Australia.
German Diabetes Centre, Leibniz Centre for Diabetes Research at the Heinrich Heine University, Dusseldorf, Germany.
Nat Rev Cardiol. 2025 Jan 13. doi: 10.1038/s41569-024-01115-w.
Atherosclerosis is a disease of large and medium arteries that can lead to life-threatening cardiovascular and cerebrovascular consequences, such as myocardial infarction and stroke. Moreover, atherosclerosis is a major contributor to cardiovascular-related mortality in individuals with diabetes mellitus. Diabetes aggravates the pathobiological mechanisms that underlie the development of atherosclerosis. Currently available anti-atherosclerotic drugs or strategies solely focus on optimal control of systemic risk factors, including hyperglycaemia and dyslipidaemia, but do not adequately target the diabetes-exacerbated mechanisms of atherosclerotic cardiovascular disease, highlighting the need for targeted, mechanism-based therapies. This Review focuses on emerging pathological mechanisms and related novel therapeutic targets in atherosclerotic cardiovascular disease in patients with diabetes.
动脉粥样硬化是一种发生在大中动脉的疾病,可导致威胁生命的心血管和脑血管后果,如心肌梗死和中风。此外,动脉粥样硬化是糖尿病患者心血管相关死亡率的主要促成因素。糖尿病会加剧动脉粥样硬化发展的病理生物学机制。目前可用的抗动脉粥样硬化药物或策略仅专注于对全身风险因素的最佳控制,包括高血糖和血脂异常,但并未充分针对糖尿病加剧的动脉粥样硬化性心血管疾病机制,这凸显了针对性的、基于机制的治疗的必要性。本综述重点关注糖尿病患者动脉粥样硬化性心血管疾病中新兴的病理机制和相关的新型治疗靶点。